Navigation Links
Study Says Allergy Shots Help Children, Reduce Health Care Costs
Date:1/23/2008

BioMedEcon Study, First of its Kind in US, Finds Allergy Immunotherapy

Beneficial Even When Treatment Not Completed

MOSS BEACH, Calif., Jan. 23 /PRNewswire/ -- BioMedEcon, a leading provider of health economics and outcomes research, today announced findings of a landmark study which show allergy immunotherapy (IT) delivers important clinical benefits to children and significantly reduces health care costs, even when the appropriate course of treatment is not completed. The study of 520 low-income Florida children with allergic rhinitis found that IT was associated with significant savings across all aspects of the health care system -- inpatient, outpatient and medication treatments -- even among children who completed only a fraction of the recommended three-year treatment regimen. The study is published in the January 2008 issue of The Journal of Allergy and Clinical Immunology (JACI).

The BioMedEcon study, a first of its kind in the United States, examined nine years of data (1997-2006) on children in the Florida Medicaid program to compare health costs for the six-month period before the initiation of IT to the six-month period following IT discontinuation. Adherence to the treatment program was poor, with 39 percent of the children receiving less than six months of IT, and only 16 percent completing at least three years of IT. However, the study found that the benefits extended across children in the sample, with strikingly reduced numbers of hospitalizations, doctor's visits and prescription drugs following treatment.

"These findings are remarkable," said Cheryl S. Hankin, Ph.D., president and CSO of BioMedEcon, LLC. "Even though most of the children in our study had insufficient treatment duration, averaging less than half of the recommended course, their health care use and costs significantly declined following treatment. It is clear that allergy immunotherapy not only benefits children with allergic rhinitis, b
'/>"/>

SOURCE BioMedEcon, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
3. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
4. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
5. Northwestern Memorial Transplant Program Initiates New Study
6. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
7. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
10. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Johnson & Johnson (NYSE: ... 10 a.m. (Eastern Time) on Thursday, April 23, 2015, from ... Investors and other interested parties may access ... Company,s website at www.jnj.com and clicking on the ... meeting will be made available a few hours after the ...
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
(Date:3/26/2015)... , March 26, 2015 "Whether it,s our ... one day." In a single sentence, ... scientific officer at Pfizer,s Centers for Therapeutic Innovation ... scientists fueling progress at America,s biopharmaceutical companies. ... side-by-side with academia, patient foundations and the National Institutes ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... publishes largest study comparing cancer risk of ezetimibe ... -BOSTON, March 25 A new study shows ... ezetimibe/simvastatin combination treatments, compared to cancer rates of ... conducted by Tufts Medical Center lipid and health ...
... N.J., March 25 DOR BioPharma, Inc. (OTC Bulletin ... company, announced today that it has entered into a ... with its clinical trials management partner, Numoda Corporation (Numoda). ... be completed in January 2010. This investment follows ...
Cached Medicine Technology:Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 3DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 4DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 5
(Date:3/28/2015)... One in three young athletes who undergo ... at the American Orthopaedic Society for Sports Medicine’s ( ... term success of surgery for patients aged 18 years ... 242 patients who underwent ACL reconstruction between 1993 and ... from North Sydney Orthopaedic and Sports Medicine Centre. “Of ...
(Date:3/28/2015)... California (PRWEB) March 28, 2015 Andrew Hawley ... original 1960's Who psychedelic concert posters. The Who and the ... York on August 2, 1968. According to Hawley, “The Who ... many concert halls and college campuses. Perhaps the most famous ... with Jim Morrison and the Doors on August 2, 1968 ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Designers and ... new overlay entitled Scratches 5K from Pixel Film Studios. ... effects to any media inside Final Cut Pro X” ... Corporate saves time and is an effective tool for ... FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply drag ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... First Choice Emergency Room opened its new Summerwood ... W Lake Houston Pkwy, Houston, Texas and is open 24-7. ... to delivering the highest quality emergency medical care to my ... Choice Emergency Room Summerwood. , To celebrate the ... Creek High School at First Choice Emergency Room’s ribbon cutting ...
Breaking Medicine News(10 mins):Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2
... with rheumatoid arthritis (RA), the most common chronic ... individuals to experience depression. Although depression in primary ... examined whether rheumatologists and RA patients discuss depression ... the February issue of Arthritis Care & Research ...
... Key to Behavior Change & Decrease in ... Disparities in care of,diabetes patients in ... interventions, according to a new,study published in ... Rates of,glucose control testing among Latinos with ...
... Care and HealthEOS announced today that they have reached an agreement ... ... As a result of the settlement,agreement, WPS customers that use the ... facilities through the end of,2008. The services provided to these WPS ...
... Feb. 1 The Obesity Action,Coalition (OAC) is calling ... House Bill 282 (HB 282) that discriminates,against those affected ... The OAC strongly feels that HB 282 is outright ... often misguided attempts,proposed to address the obesity epidemic., ...
... Association (APHA) today released its annual congressional record,which measures ... to public health., APHA,s report was compiled by ... votes during the first session of the 110th,Congress in ... senators voted in support of APHA,s,position on all eight ...
... - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division ... retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein ... to severe plaque psoriasis following 12 weeks of treatment. ... greater in the ENBREL treated group compared to the ...
Cached Medicine News:Health News:Depression not discussed during rheumatoid arthritis doctor visits 2Health News:Lumetra Program Improves Diabetes Care Among Latinos 2Health News:Wisconsin Physicians Service Insurance Corporation, Aurora Health Care and HealthEOS Announce Settlement Agreement 2Health News:Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity 2Health News:APHA Scores Members of Congress on Public Health Voting Record 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
... a scope designed specifically to enable direct ... also suitable for pediatric applications as well. ... a mere 2.8mm across. As a result, ... accomplished with greater ease. And since this ...
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
... Double lumen tubes ... ventilation., ,Each ... is packaged with ... adaptors, suction catheters ...
... a double lumen tube made of silicone rubber ... ,Due to the characteristics of silicone rubber, Silbronco ... at insertion. Furthermore, the tube will not soften ... long term surgery., ,Silbronco is also especially ...
Medicine Products: